DEEP NOID Inc.

DEEP NOID Inc.

KKRX:315640
1,459.00
KRW
-56.00
(-3.70%)
-534.89EPS
46.64BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
137.75
18.25
72.44
48.05
146.37
45.58
439.31
328.14
168.34
Basic EPS, GAAP
-1,065.34
-668.19
-947.35
-450.77
-245.39
-158.85
-367.63
-472
-534.89
Free Cash Flow per Basic Share
-391.55
-202.94
-283.47
-300.99
-194.79
-131.74
-943.58
-317.87
-440.33
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-391.3
-785.51
-98.84
633.48
457.29
1,115.08
770.91
969.59
727.61
Tangible Book Value per Share
-391.79
-787.84
-103.75
627.45
452.29
1,111.42
767.6
967.52
725.58
Basic Weighted Avg Shares
6
13
14
20
22
42
25
23
27
Sales/Revenue/Turnover
887
235
1,040
944
3,182
1,933
10,847
7,472
4,508
Operating Margin (%)
-171.22
-1,798.2
-481.64
-810.83
-193.57
-347.99
-93.07
-141.29
-311.32
Depreciation Expense
171
151
222
381
614
671
878
943
954
Net Income, GAAP
-6,861
-8,606
-13,600
-8,854
-5,334
-6,737
-9,078
-10,748
-14,323
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-773.36
-3,660.65
-1,307.75
-938.2
-167.65
-348.52
-83.69
-143.84
-317.75
Working Capital
5,882
-7,834
9,121
15,045
8,851
26,251
15,684
25,397
18,490
LT Debt
289
275
182
352
371
224
6,830
6,825
6,767
Total Equity
-9,011
-18,089
-2,276
13,748
9,966
27,178
19,041
28,479
21,372
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-44.99
-36.28
-39.28
-45.23
-77.48

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
131
166
141
LT Borrowings
6,660
6,660
6,660
LT Finance Leases
165
135
107
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29
29
29
Market Capitalization
95,313
96,928
46,643

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
27,645
23,951
20,292
Cash, Cash Equivalents & STI
23,949
18,450
15,950
Accounts Receivable, Net
77
384
370
Inventories
- -
- -
- -
Total Current Liabilities
2,249
2,971
1,802
Payables & Accruals
- -
- -
- -
ST Debt
131
166
141
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-107.85%
49.56%
Free Cash Flow
- -
59.39%
-68.93%
Net Income, GAAP
- -
0.96%
18.4%
Sales/Revenue/Turnover
- -
123.74%
-31.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
358
3,872
3,979
2,638
10,847
2025
961
3,671
2,180
659
7,472
2026
357
1,311
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-114
-95.31
-68.99
-102.22
-367.63
2025
-141.61
-0.91
-122.74
-177.92
-472
2026
-131.86
-110
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Woo-Sik Choi
Full Time Employees
183
Sector
Technology services
Industry
Packaged software
Address
Seoul South Korea
IPO Date
Aug 17, 2021
Business
DEEP NOID Inc. is a South Korea-based artificial intelligence technology company that specializes in the development and commercialization of deep learning-driven medical diagnostic software, clinical AI development platforms, and automated industrial security inspection systems. Founded in 2008 and headquartered in Seoul, South Korea, the company operates primarily across two core business segments: Medical AI and Industrial AI. The company offers a comprehensive portfolio of proprietary software solutions, including M4CXR, a generative artificial intelligence solution that analyzes chest radiographs to automatically draft preliminary medical reading reports; DEEP:NEURO, a deep learning-based diagnostic aid software for the automated detection and localization of cerebral aneurysms on brain magnetic resonance angiography images; DEEP:CHEST, an AI-enabled chest X-ray analysis solution for the detection of multiple pulmonary diseases and abnormal thoracic conditions; DEEP:SPINE, a computer-aided diagnostic tool for spinal disorders; DEEP:PHI, an open, no-code medical AI development platform that allows medical practitioners and researchers without programming backgrounds to design, train, and validate customized AI models; DEEP:PACS, an AI-integrated Picture Archiving and Communication System designed for medical imaging storage, transmission, and diagnostic workflow integration; DEEP:STORE, a digital marketplace for deploying and sharing verified clinical AI algorithms; DEEP:SECURITY, also offered as SkyMARU:SECURITY, an AI-powered automated X-ray screening system that detects hazardous materials and contraband for aviation, customs, and public security checkpoints; and DEEP:FACTORY, an industrial machine vision solution providing automated defect inspection and quality assurance for smart manufacturing facilities. The company serves university hospitals, tertiary medical centers, research institutions, government agencies, international airports, and industrial manufacturers, with operational reach centered in South Korea and expanding into broader Asia-Pacific, European, and North American markets. In recent operational developments, DEEP NOID obtained medical device approval from South Korea's Ministry of Food and Drug Safety for its generative AI solution M4CXR and entered into multi-hospital software supply agreements with major tertiary institutions, including Jeonbuk National University Hospital and Hwasun Chonnam National University Hospital, while initiating the regulatory pathway toward national health insurance reimbursement coverage. This follows the provisional national health insurance coverage listing for its DEEP:NEURO and DEEP:CHEST systems in South Korea. In its security division, DEEP NOID established a strategic testing and integration agreement with global security technology provider Smiths Detection to incorporate its proprietary threat-detection AI software into dual-view X-ray security inspection equipment. Additionally, the company is transitioning its commercialization framework toward hospital software subscription models and per-case diagnostic billing, while broadening its generative AI research and development roadmap to encompass CT and MRI modalities integrated with hospital Electronic Medical Records and clinical communications systems.